Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 2;2(2):119-23.
doi: 10.1021/ml100192b. eCollection 2011 Feb 10.

Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars

Amar Ghisaidoobe  1 , Pieter Bikker  1 , Arjan C J de Bruijn  1 , Frithjof D Godschalk  1 , Eva Rogaar  1 , Marieke C Guijt  1 , Peter Hagens  1 , Jerre M Halma  1 , Steven M Van't Hart  1 , Stijn B Luitjens  1 , Vincent H S van Rixel  1 , Mark Wijzenbroek  1 , Thor Zweegers  1 , Wilma E Donker-Koopman  2 , Anneke Strijland  2 , Rolf Boot  2 , Gijs van der Marel  1 , Herman S Overkleeft  1 , Johannes M F G Aerts  2 , Richard J B H N van den Berg  1
Affiliations

Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars

Amar Ghisaidoobe et al. ACS Med Chem Lett. .

Abstract

Glucosylceramide synthase (GCS) is an important target for clinical drug development for the treatment of lysosomal storage disorders and a promising target for combating type 2 diabetes. Iminosugars are useful leads for the development of GCS inhibitors; however, the effective iminosugar type GCS inhibitors reported have some unwanted cross-reactivity toward other glyco-processing enzymes. In particular, iminosugar type GCS inhibitors often also inhibit to some extent human acid glucosylceramidase (GBA1) and the nonlysosomal glucosylceramidase (GBA2), the two enzymes known to process glucosylceramide. Of these, GBA1 itself is a potential drug target for the treatment of the lysosomal storage disorder, Gaucher disease, and selective GBA1 inhibitors are sought after as potential chemical chaperones. The physiological importance of GBA2 in glucosylceramide processing in relation to disease states is less clear, and here, selective inhibitors can be of use as chemical knockout entities. In this communication, we report our identification of a highly potent and selective N-alkylated l-ido-configured iminosugar. In particular, the selectivity of 27 for GCS over GBA1 is striking.

Keywords: Gaucher; acid glucosylceramidase; deoxynojirimycin; glucosylceramide synthase; type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Reported GCS inhibitors.
See this image and copyright information in PMC

References

    1. Brady R. O.; Kanfer J. N.; Bradley R. M.; Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J. Clin. Invest. 1966, 45, 1112–1115. - PMC - PubMed
    1. Platt F. M.; Neises G. R.; Dwek R. A.; Butters T. D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 1994, 269, 8362–8365. - PubMed
    1. Cox T.; Lachmann R.; Hollak C.; Aerts J.; van Weely S.; Hrebícek M.; Platt F.; Butters T.; Dwek R.; Moyses C.; Gow I.; Elstein D.; Zimran A. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000, 355, 1481–1485. - PubMed
    1. Elstein D.; Dweck A.; Attias D.; Hadas-Halpern I.; Zevin S.; Altarescu G.; Aerts J. F. M. G.; van Weely S.; Zimran A. Oral maintenance clinical trial with miglustat for type I Gaucher disease: Switch from or combination with intravenous enzyme replacement. Blood 2007, 110, 2296–2301. - PubMed
    1. Aerts J. M. F. G.; Hollak C. E. M.; Boot R. G.; Groener J. E. M.; Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J. Inherited Metab. Dis. 2006, 29, 449–456. - PubMed